Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperlithemia correction and persistent delirium

C M Swartz1, P Jones

  • 1Department of Psychiatric Medicine, East Carolina University School of Medicine, Greenville, North Carolina 27858-4354.

Journal of Clinical Pharmacology
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Charcoal enhancement of treatment for tricyclic-induced mania.

Pharmacopsychiatry·2002
Same author

Long-term outcome after ECT for catatonic depression.

The journal of ECT·2001
Same author

Olanzapine-lithium encephalopathy.

Psychosomatics·2001
Same author

Inclusion of patients who cannot respond to ECT blocks observation of EEG findings.

The journal of ECT·2001
Same author

Stimulus dosing in electroconvulsive therapy and the threshold multiple method.

The journal of ECT·2001
Same author

ECT failure rate among specific devices.

The American journal of psychiatry·2001
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
See all related articles

Rapid correction of hyperlithemia, often seen with lithium treatment, can cause delirium and lasting neurologic issues. Gradual correction may reduce the risk of this lithium-induced neurotoxicity.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Lithium is a common treatment for bipolar disorder.
  • Hyperlithemia, or high lithium levels, can occur with regular dosing.
  • Neurologic complications are a concern with lithium therapy.

Observation:

  • Three patient cases indicated delirium and persistent neurologic dysfunction after rapid hyperlithemia correction.
  • A review of 65 adult hospitalizations for hyperlithemia revealed cognitive dysfunction post-lithium.
  • Lithium was discontinued before or upon admission in selected cases.

Findings:

  • 56% of patients with initial responsiveness experienced deterioration during hospitalization.
  • Dialysis correlated with higher rates of persistent neurologic sequelae (62%) and in-hospital deterioration (85%).

Related Experiment Videos

  • Despite lower initial cognitive dysfunction, dialysis patients showed worse outcomes.

    • Implications:

    • Rapid correction of hyperlithemia, particularly via dialysis, may increase neurotoxicity.
    • Gradual correction of hyperlithemia, similar to hyponatremia management, could mitigate neurologic risks.
    • This suggests a need for cautious lithium level management to prevent adverse neurologic events.